Björn Peters1,2, Henrik Hadimeri1, Johan Mölne3, Salmir Nasic4, Gert Jensen5, Bernd Stegmayr2. 1. Department of Nephrology, Skaraborg Hospital, Skövde, Sweden. 2. Department of Public Health and Clinical Medicine, Umeå University, Gothenburg, Sweden. 3. Department of Pathology, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden. 4. Department of Research Center (FoU), Skaraborg Hospital, Skövde, Sweden. 5. Department of Nephrology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Abstract
AIM: To evaluate whether the administration of desmopressin alters the risk for renal biopsy complications. METHODS: A multicenter registry containing 576 native kidney biopsies (NKb) with a serum creatinine above 150 μmol/L in 527 patients (372 men and 155 women, median age 61 years) was used. Most of the data were prospective. At one of the hospitals all biopsies with creatinine above 150 μmol/L received desmopressin before biopsies (NKb 204). These were compared to outcome of biopsy complications against other centres where desmopressin was not given (NKb 372). Fisher's exact test, χ2 analyses, univariate and multiple binary logistic regression were used. Data were given as odds ratio (OR) and confidence interval (CI). A two sided P-value of <0.05 was considered significant. RESULTS: In NKb with creatinine >150 μmol/L, those with desmopressin had less overall (3.4% vs 8.4%, OR 0.39, CI 0.17-0.90) whereas major or minor complications were not different. While desmopressin did not exhibit difference in complications in men, women received less major (0% vs 8.6%, P = 0.03) and overall complications (0% vs 12.1%, P = 0.006). A multiple logistic regression revealed that, after adjusting for BMI, age and sex, prophylaxis with desmopressin showed less major (OR 0.38, CI 0.15-0.96) and overall complications (OR 0.36, CI 0.15-0.85). CONCLUSION: Desmopressin given before a native kidney biopsy in patients with impaired renal function can reduce the risk for complications.
AIM: To evaluate whether the administration of desmopressin alters the risk for renal biopsy complications. METHODS: A multicenter registry containing 576 native kidney biopsies (NKb) with a serum creatinine above 150 μmol/L in 527 patients (372 men and 155 women, median age 61 years) was used. Most of the data were prospective. At one of the hospitals all biopsies with creatinine above 150 μmol/L received desmopressin before biopsies (NKb 204). These were compared to outcome of biopsy complications against other centres where desmopressin was not given (NKb 372). Fisher's exact test, χ2 analyses, univariate and multiple binary logistic regression were used. Data were given as odds ratio (OR) and confidence interval (CI). A two sided P-value of <0.05 was considered significant. RESULTS: In NKb with creatinine >150 μmol/L, those with desmopressin had less overall (3.4% vs 8.4%, OR 0.39, CI 0.17-0.90) whereas major or minor complications were not different. While desmopressin did not exhibit difference in complications in men, women received less major (0% vs 8.6%, P = 0.03) and overall complications (0% vs 12.1%, P = 0.006). A multiple logistic regression revealed that, after adjusting for BMI, age and sex, prophylaxis with desmopressin showed less major (OR 0.38, CI 0.15-0.96) and overall complications (OR 0.36, CI 0.15-0.85). CONCLUSION: Desmopressin given before a native kidney biopsy in patients with impaired renal function can reduce the risk for complications.
Authors: Sheila Bermejo; Clara García-Carro; Richard Mast; Ander Vergara; Irene Agraz; Juan Carlos León; Monica Bolufer; Maria-Alejandra Gabaldon; Daniel Serón; Oriol Bestard; Maria Jose Soler Journal: J Clin Med Date: 2022-03-07 Impact factor: 4.241